Enzymatica AB is a Swedish life science company that develops and sells health care products primarily for conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about ten markets.
The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. During 2019 Enzymatica has entered an agreement with its German collaboration partner STADA regarding sales of a new mouth spray for the German market, and signed an agreement with the German company Maren Cosmetics of delivery of an enzyme formulation for their skin care products. In addition, ABEX Pharmaceutica (PTY) LTD started to sell ColdGuard® (ColdZyme) on the South African market.